<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="601">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153330</url>
  </required_header>
  <id_info>
    <org_study_id>BF-MNN-101</org_study_id>
    <nct_id>NCT05153330</nct_id>
  </id_info>
  <brief_title>Ph1 FIH Dose-escalation and Dose-expansion Study of BMF-219, in Adult Patients With Acute Leukemia</brief_title>
  <official_title>Phase1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Irreversible Menin Inhibitor, in Adult Patients With Acute Leukemia Including Those With an MLL/KMT2A Gene Rearrangement or NPM1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomea Fusion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biomea Fusion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral&#xD;
      Irreversible Menin Inhibitor, in Adult Patients With Acute Leukemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral&#xD;
      Irreversible Menin Inhibitor, in Adult Patients With Acute Leukemia including those with an&#xD;
      MLL/KMT2A gene arrangement or NPM1&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">June 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two parallel dose escalation arms; ARM A (subjects not receiving CYP3A4 inhibitors) and ARM B (subjects receiving CYP3A4 inhibitors).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Optimal Biologic Dose (OBD)</measure>
    <time_frame>28 days</time_frame>
    <description>Determine the OBD and recommended phase 2 dose (RP2D) of BMF-219 monotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Safety by treatment-emergent TEAEs and SAEs</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluate safety as expressed by treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Mixed-Phenotype Leukemia</condition>
  <condition>Cancer</condition>
  <condition>Refractory</condition>
  <condition>Progression</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants will receive BMF-219. Arm A: Subjects who are not receiving CYP3A4 inhibitors. Arm B: Subjects who are receiving CYP3A4 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with relapsed/refractory acute leukemia will receive the Optimal Biologic Dose (OBD) or Recommended Phase 2 Dose (RP2D) of BMF-219 as determined from the Dose Escalation Phase of the study to further assess safety and tolerability of BMF-219 and to identify initial efficacy signals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMF-219</intervention_name>
    <description>BMF-219 is orally administered once daily in continuous 28 day cycles.</description>
    <arm_group_label>Dose Escalation Phase</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
    <other_name>Irreversible Menin Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or pathologically confirmed diagnosis and/or measurable Refractory or&#xD;
             relapsed acute leukemia defined as &gt; 5% blasts in the bone marrow or reappearance of&#xD;
             blasts in the peripheral blood.&#xD;
&#xD;
          -  Have failed or are ineligible for any approved standard of care therapies, including&#xD;
             HSCT&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  ECOG performance status of 0-2&#xD;
&#xD;
          -  Adequate liver function: total serum bilirubin ≤ 1.5 × upper limit of normal (ULN)&#xD;
             except for Gilbert's syndrome or non-hepatic origin such as hemolysis; aspartate&#xD;
             aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.0 × ULN&#xD;
&#xD;
          -  Adequate renal function: Estimated creatinine clearance (eCrCl) ≥ 60 mL/min using the&#xD;
             Cockcroft-Gault equation (Cockcroft and Gault, 1976)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of acute promyelocytic leukemia (APL)&#xD;
&#xD;
          -  Diagnosis of chronic myeloid leukemia (CML) in blast crisis&#xD;
&#xD;
          -  Isolated extramedullary relapse (iEMR)&#xD;
&#xD;
          -  WBC count &gt;25,000/ µL (uncontrollable with cytoreductive therapy)&#xD;
&#xD;
          -  Clinically active central nervous system (CNS) leukemia. Previously controlled CNS&#xD;
             leukemia is acceptable&#xD;
&#xD;
          -  Subjects who have undergone HSCT and have not had adequate hematologic recovery (i.e.,&#xD;
             ANC&gt;500 and platelet count &gt;50K&#xD;
&#xD;
          -  Subjects who received chemotherapy, immunotherapy, or radiotherapy or any ancillary&#xD;
             therapy that is considered to be investigation (i.e., used for non-approved indication&#xD;
             and in the context of research investigation) &lt; 14 days prior to the first dose of&#xD;
             BMF219 or within 5 drug half-lives (whichever is shorter) prior to the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Prior menin inhibitor therapy&#xD;
&#xD;
          -  Know positive test for human immunodeficiency virus, hepatitis C or hepatitis B&#xD;
             surface antigen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Cacovean, MD</last_name>
    <role>Study Director</role>
    <affiliation>Biomea Fusion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bhagyashree Yadav, MD</last_name>
    <phone>650-980-9099</phone>
    <email>byadav@biomeafusion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph Suttner, MBA</last_name>
    <phone>650-980-9099</phone>
    <email>jsuttner@biomeafusion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Lancet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashwin Kishtagari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhad Ravandi-Kashani, MD</last_name>
    </contact>
    <investigator>
      <last_name>Farhad Ravandi-Kashani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

